ESACT Innovation Award Lecture
Presented by Terry Papoutsakis, Chair of the ESACT Innovation Award
Committee (ESACT Honorary Member & University of Delaware, USA)

ESACT Innovation Award Committee is pleased to present the 2022 awardees:
Richard Wales and Neil Bargh for innovation in automated cell cultures technologies to support the development of biotherapeutics

ESACT Innovation Award Lecture:

Ambr15; how it happened and what was important

Scientific Session: Bio breakthroughs
Chairs:
Luís Almeida, CNC Univ de Coimbra, Portugal              
Laura Cervera, Univ Autònoma Barcelona, Spain

18:00-18:20

INV 1 - Manipulating exosome biogenesis to enhance productivity of recombinant cell lines producing engineered exosome therapeutics
Scott Estes, Codiak BioSciences, United States

18:20-18:40  

INV 2 - Innovating the Manufacturing of Human Mesenchymal Stromal Cells (MSC) and MSC-derived Products through Bioengineering
Claudia Lobato da Silva, IBB, IST, Univ de LSiboa, Portugal

18:40-18:50  

O 1 - Preservation of critical quality attributes in 3D bioprinted cell-based structures by using natural hydrogels
Joaquim Vives, Banc de Sang i Teixits, Spain

18:50-19:00  

O 2 - Turning an old medicine into a new therapeutical candidate: from erythropoietin to a novel hyperglycosylated, non-erythropoietic but neuroprotective analogue
Marcos Oggero, UNL, CONICET, FBCB, Centro Biotecnológico del Litoral/BioSynaptica SA, Argentina

19:00-19:10 

O 3 - Systems-level discovery of quality attributes and candidate pathways for optimized production of human pluripotent stem cell-derived cardiomyocytes
Aaron Simons, NSF ERC for Cell Manufacturing Technologies (CMaT), United States

19:10-19:20 

O 4 - Human stem-cell based models to study innate immunity and neuroinflammation in the central nervous system
Catarina Gomes, iBET, Instituto de Biologia Experimental e Tecnológica, Portugal

Exhibitors Reception at the Exhibition Hall

Introduction to The Porto wine
by Vasco Magalhães (Wine expert) & Teresa Gomes (Sommelier) & tasting
Cocktal reception

Poster Student Highlights
Chairpersons:

Nusa Pristovsek, ESACT Frontiers & Novo Nordisk, Denmark
Claire Pearce, ESACT Frontiers & XAP Therapeutics, UK
Francisca Arez, iBET, Portugal

H1 - 3D Bioprinted Cellular Structures for Universal Production of Therapeutics
Laura Chastagnier, 3d.Fab – ICBMS, France

H2 - Semi-continuous propagation of influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates
Lars Pelz, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

H3 - Extracellular Vesicles packaging and delivery of silencing sequences to alleviate a brain disorder
David Rufino-Ramos, CNC - Center for Neuroscience and Cell Biology of University of Coimbra, Portugal

H4 - Single-cell and Bulk RNA sequencing of insect Sf9 cells during rAAV production
Nikolaus Virgolini, iBET - Instituto de Biologia Experimental e Tecnológica, Portugal

H5 - Reverse genetics for Influenza A virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination
Tanya Dogra, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

H6 - Investigating “Difficult-to-Express” mAb Frameworks in Transient and Site-Specific Integration-Based CHO Expression Systems
Alana C. Szkodny, University of Delaware, United States

H7 - Artificial miRNAs allow stepwise adjustment of core-fucosylation in CHO cells
Patrick Schlossbauer, Biberach University of Applied Sciences, Germany

H8 - Raman spectroscopy for monitoring of amino acids and antibody glycosylation in high cell density perfusion culture
Hubert Schwarz, Competence Centre for Advanced BioProduction Continuous Processing (AdBIOPRO), Royal Institute of Technology (KTH), Sweden

H9 - Lectin-aided flow cytometry reveals a close correlation between cell surface and mAb glycosylation
Mina Ghahremanzamaneh, School of Chemical and Bioprocess Engineering, University College Dublin, Republic of Ireland

H10 - Development of novel fast-growing Chinese hamster lung (CHL)-YN cells in serum-free fed-batch for monoclonal antibody production
Puriwat Sukwattananipaat, Graduate School of Engineering, Osaka University, Japan

H11 - Downstream process design and optimization of GAG HIV-1 based Virus-Like Particles
Elianet Lorenzo Romero, Universitat Autònoma de Barcelona, Spain

Scientific Session: Data, Data, Data: how to get it and how to use it
Chairpersons:
Mike Betenbaugh, John Hopkins Univ, USA
Damian Marshal, Achilles Therapeutics UK limited, UK

11:00-11:25

INV 3 - What can extracellular data tell us about intracellular pathways?
Cleo Kontoravdi, Imperial College London, United Kingdom

11:25-11:50

INV 4 - Bioprocessing in the Digital Age: from Process Models, through the Integration of Machine Learning, to Digital Twins
Alessandro Butté, DataHow AG, Switzerland

11:50-12:03

O 6 – Biomarker identification for in silico performance prediction of CHO cell lines expressing complex therapeutic Abs
Stylianiv Papadaki, Roche Diagnostics GmbH, Germany

12:03-12:16

O 7 – On Digital Bioprocessing and Manufacturing Intelligence: Application of Process Analytical Technology and data analytics for upstream process development and intensification
Ricardo Suarez Heredia, University College London/University of Cambridge/Merck KGaA, United Kingdom

12:16-12:29

O 8 – Bioprocess digital twins for biomanufacturing 4.0
Dong-Yup Lee, SungKyunKwan University, Korea (South, Republic of)

Scientific Session: Beyond Evolution
Chairpersons:
Martin Fussenegger (ETH, Switzerland)
Nick Timmins (Artisan Bio, USA)

16:00-16:30

INV 5 - CAR T-cell immunotherapy of solid tumours: Parallel learning from the clinic and lab
John Maher King´s College London, United Kingdom

16:30-16:40

O 9 – Blueprint from nature: Multi-omics comparison of CHO and plasma cells unveils novel cell engineering targets to improve productivity
Nikolas Zeh, Boehringer Ingelheim Pharma GmbH, Germany

16:40-16:50

O 10 – Enabling large therapeutic gene delivery: improving dual AAV vector-intein mediated systems
Mariana Ferreira, ITQB NOVA & iBET, Portugal

16:50-17:00

O 11 – Theranostic cells for detection and counteraction of infections by rewiring cellular host defense pathways
Dagmar Wirth, Helmholtz Centre for Infection Research, Germany

17:00-17:10

O 12 – Viral protease-based molecular switches for drug discovery and synthetic biology applications
Nik Franko, ETHZ, Switzerland

17:10-17:15

Flash 1 – Expanding The Design Space of Synthetic Promoters for CHO Cell Engineering Using Next-Generation Sequencing
Adrian Bourke, University of Sheffield, United Kingdom

17:15-17:20

Flash 2 – Multiplexed engineering CHO cells to produce recombinant IgGs with desirable N-glycans via targeted integration
Nguyen Tran Bich Ngan, Bioprocessing Technology Institute, A*STAR, Singapore

Scientific Session: Molecular Cell Surgery
Chairpersons:
Isabelle Rivière, Memorial Sloan Kettering Cancer Center, USA
Nicole Borth, BOKU, Austria

18:00-18:25

INV 6  - Turning Genes into Medicines: Prospects and Problems in Development of a Novel Class of Therapeutics
Kathy High, AskBio, Therapeutics, United States

18:25-18:50

INV 7 - Guiding mRNA-LNP drug products from early R&D programs to the market – Scale up and production of mRNA LNPs
Andreas Wagner, Polymun Scientific, Austria

18:50-19:00

O 13 – Repairing the repairers: Stabilizing the CHO genome and protein production by editing DNA repair
Nathan Lewis, University of California, San Diego, United States

19:00-19:10

O 14 – Influenza A virus-derived defective interfering particles for antiviral treatment
Sascha Kupke, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

19:10-19:20

O 15 – An arrayed CRISPR screen reveals Myc depletion to increase productivity of difficult-to-express complex antibodies in CHO cells
Niels Bauer, Roche Diagnostics GmbH, Germany

19:20-19:25

Flash 3 – Engineered nucleases targeting the ATXN3 gene for the therapy of Machado-Joseph disease
Sara Lopes, Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Portugal

19:25-19:30

Flash 4 – Rational development of recombinant CHO cells based on histone analysis: Identification and experimental validation of stable integration sites
Oliver Hertel, Bielefeld University, Germany

Selected Flash Presentations Session

Chairpersons:  

Emma Petiot, 3d.FAB/UCBL, France

Niall Barron,  NIBRT, Ireland

Flash 5 – 4-1BB and 4-1BBxOX40 bispecific Anticalin®-based payloads to armor cellular immunotherapies for effective localized immune cell stimulation
Janet Peper-Gabriel, Pieris Pharmaceuticals GmbH, Germany

Flash 6 – Culture of Pluripotent Stem Cells and Derivation of Organoids using Droplet Microfluidics
Sebastien Sart, Institut Pasteur, France

Flash 7 – Augmented decision making for cell culture process development: from data traceability & accessibility to process modelling
Wolfgang Paul, Upstream Process Sciences Biotech Sciences, UCB Pharma S.A., Belgium

Flash 8 – Found in translation: Microproteins are a new class of potential host cell impurity in mAb drug products
Colin Clarke, NIBRT, Republic of Ireland

Flash 9 – Using a cell receptor knock-out strategy to enable stable expression of cytotoxic envelope glycoproteins for lentiviral vector production
Rodrigo Nogueira, iBET- Instituto de Biologia Experimental e Tecnológica, Portugal

Flash 10 – Endogenous BiP reporter system for simultaneous identification of ER stress and antibody production in Chinese hamster ovary cells
Jae Seong Lee, Ajou University, Korea (South, Republic Of)

Scientific Session: Challenges and Marvels of Bioprocess Intensification (part I)
Chairpersons:
Chetan Goudar, Amgen, USA
Paulo Fernandes, Orchad, Uk
Stefanos Grammatikos, UCB, Belgium

16:00-16:25

INV 9  - Process Intensification Opportunities, Challenges and Solutions: Product Quality, Harvest and Scale Up Considerations for Intensified Processes
Bassem Bem Yahia, UCB Pharma, Belgium

16:25-16:40

O 19 - Process intensification and connected processing for robust, cost effective, and fast manufacturing of monoclonal antibodies
Sanket Jadhav, Sartorius, Netherlands & Abijar Bhori, Enzene Biosciences, Pune, India

16:40-16:55

O 20 - Overcoming product retention in TFF-based perfusion cell cultures by using low shear magnetically levitating pumps
Magdalena Pappenreiter, Bilfinger Life Science GmbH, Innovation Management; University of Natural Resources and Life Sciences (BOKU), Austria

16:55-17:10

O 21 - Migrating a months-long perfusion process to intensified fed-batch
Lena Thoring, FyoniBio GmbH, Germany

17:10-17:35

INV 10  - Enabling Intensified Bioprocesses At Scale

Daniel Karst, Biogen International GmbH, Switzerland

Scientific Session: Adaptive manufacturing: engineering quality into your process (part II)
Chairpersons:
Anne Tolstrup, AbtBioConsult, Denmark
Laura Palomares, IBT-UNAM, Mexico

11:30-12:00

INV 11 - Next-generation, feedback responsive cell factories for recombinant protein manufacturing
Laura Segatori, Rice University, United States

12:00-12:15

O 22 – Identification and Control of Novel Waste Inhibitory Metabolites In CHO Cell-Cultures
Seongkyu Yoon, University of Massachustts Lowell, United States

12:15-12:30

O 23 – State-of-the-art strategies for adeno-associated virus product homogeneity assessment
Marco Radukic, Biofidus AG / Bielefeld University, Germany

Scientific Session: Challenges and Marvels of Bioprocess Intensification (part II)
Chairpersons:
Chetan Goudar, Amgen, USA
Paulo Fernandes, Orchad, Uk
Stefanos Grammatikos, UCB, Belgium

14:30-14:45

O 24 – Optimization of continuous HIV-1 Gag virus-like particles (VLPs) harvest using an alternative perfusion approach
Jesus Lavado, Universitat Autònoma de Barcelona (UAB), Spain

14:45-15:00

O 25 – The perks of innovating influenza VLP-based vaccine production
Antonio Roldao, IBET & ITQB-NOVA, Portugal

15:00-15:15

O 26 – Cell Therapy Process Development with a 2 ml Continuous Perfusion Bioreactor
Kevin Lee, Erbi Biosystems Inc., United States

15:15-15:30

O 27 – Ultracentrifugation for AAV manufacturing: non-linear scale-up improves quality & scalability
Duarte Martins, Takeda, Austria

15:30-15:35

Flash 14 – Intensify Viral Vector Manufacturing Using Tangential Flow Depth Filtration (TFDF) platform
Rachel Legmann, Repligen corp, United States

15:35-15:40

Flash 15 – A scalable bioprocess strategy for rAAV2 production using a stable cell line system
Jose Escandell, iBET, Portugal

15:40-15:45

Flash 16 – Establishment of two suspension adapted stable packaging cell lines for scalable lentivirus production
Maximilian Klimpel, CSL Behring Innovation GmbH, Germany

15:45-15:50

Flash 17 – Integrated process for the production and purification of therapeutic mesenchymal stromal cell-derived extracellular vesicles
Ana Fernandes-Platzgummer, Instituto Superior Técnico, Univ Lisboa, Portugal